Product Code: RP-ID-10086011 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086011
Market Overview:
Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts 2030- By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)
"The global antidepressant drug market is estimated to be valued at ~USD 20 billion by the end of 2021 and is expected to expand at a compound annual growth rate of 3% from 2022 to 2030. The prevalence of depression is increasing, and the elderly population is increasing. The emergence of new technologies for the development of drugs with fewer side effects is driving the market.
In addition, increased awareness of disease states and required clinical needs, as well as increasing numbers of people under pressure, can drive the growth of the antidepressant drug market. However, the poor efficacy and safety of the drug, preference for non-drug therapies, and an increasing number of antidepressant patent expirations have led to a weak product portfolio, which is expected to hinder market growth.
Depression includes various mental health problems characterized by lack of positive emotions, low mood, and various related cognitive, physical, emotional, and behavioral symptoms. This is a very common disease that affects one in five Americans. There are many factors that cause depression, including factors such as genes, stress, and brain chemical reactions. According to the World Health Organization, nearly 350 million people worldwide were affected by depression in 2016. Antidepressants help maintain the balance of various hormones and chemicals in the brain and help treat depression.
DEPRESSION BREAKDOWN REVIEW :
According to depression, it is divided into major depression, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, etc. Major depression is the biggest contributor to market growth because most people are often diagnosed with this disease due to increased stress. However, OCD is the fastest growing market segment.
PRODUCT MARKET SEGMENTS REVIEW :
According to different products, it is divided into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and serotonin Reuptake inhibitors and antagonists, among others. Selective serotonin reuptake inhibitors have become the dominant market segment due to the existence of a large number of such drugs.
GLOBAL ANTIDEPRESSANT MARKET:
key geographic segmentation. According to regions, the antidepressant market is divided into North America, Europe, Asia Pacific and LAMEA. North America accounted for the largest market share in the antidepressant market in 2020 and is expected to maintain its market share throughout the forecast period. leading position.
THE MAJOR OPERATING IN THE GLOBAL ANTIDEPRESSANT MARKET INCLUDE ALKERMES:
Plc, Allergan Plc, and Bristol Myers Squibb Co.. , Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. Other major players in the value chain include Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories and AstraZeneca.
MAIN BENEFITS FOR STAKEHOLDERS:
This report involves a detailed quantitative analysis of current market trends from 2022-2030 to identify current opportunities. The market estimate is based on a comprehensive analysis of key developments in the industry. The global market has conducted a comprehensive analysis of its types, methods, technologies, end users and regions. In-depth analysis based on geography helps to understand the regional market to help with strategic business planning. The development strategy adopted by major manufacturers is to understand the competitive landscape of the market.
THE MAIN MARKET SEGMENTS OF ANTIDEPRESSANTS:
According to depression, major depression, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, other by-products, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine inhibitors and serotonin Reuptake inhibitor"
Pfizer, GlaxoSmithKline, Allergan, Forest laboratories, Takeda, Novartis, Eli Lilly
Related Reports
Proof of Quality & Reliability
